BNTC - Benitec Biopharma closes ~$17.9M underwritten public offering
- Gene therapy-focused biotechnology company Benitec Biopharma ( NASDAQ: BNTC ) closed an ~$17.9M underwritten public offering of 29.81M shares and accompanying warrants to purchase up to 29.81M shares.
- Each share was sold together with one warrant at a combined offering price of $0.60.
- The net proceeds are intended to be used for the clinical development of BB-301, including the natural history lead-in study and the Phase 1b/2a BB-301 treatment study; continued advancement of development activities for other existing and new product candidates; general corporate purposes and strategic growth opportunities.
- BNTC shares were trading -3.45% pre-market.
- Source: Press Release
For further details see:
Benitec Biopharma closes ~$17.9M underwritten public offering